JP2014510157A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510157A5
JP2014510157A5 JP2014504053A JP2014504053A JP2014510157A5 JP 2014510157 A5 JP2014510157 A5 JP 2014510157A5 JP 2014504053 A JP2014504053 A JP 2014504053A JP 2014504053 A JP2014504053 A JP 2014504053A JP 2014510157 A5 JP2014510157 A5 JP 2014510157A5
Authority
JP
Japan
Prior art keywords
hydrogen
methyl
pharmaceutically acceptable
aliphatic
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014504053A
Other languages
English (en)
Japanese (ja)
Other versions
JP5975581B2 (ja
JP2014510157A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/032642 external-priority patent/WO2012139074A2/en
Publication of JP2014510157A publication Critical patent/JP2014510157A/ja
Publication of JP2014510157A5 publication Critical patent/JP2014510157A5/ja
Application granted granted Critical
Publication of JP5975581B2 publication Critical patent/JP5975581B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014504053A 2011-04-07 2012-04-06 ミグラスタチンおよびその使用 Expired - Fee Related JP5975581B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161473131P 2011-04-07 2011-04-07
US61/473,131 2011-04-07
US201161508275P 2011-07-15 2011-07-15
US61/508,275 2011-07-15
PCT/US2012/032642 WO2012139074A2 (en) 2011-04-07 2012-04-06 Migrastatins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016113255A Division JP2016155873A (ja) 2011-04-07 2016-06-07 ミグラスタチンおよびその使用

Publications (3)

Publication Number Publication Date
JP2014510157A JP2014510157A (ja) 2014-04-24
JP2014510157A5 true JP2014510157A5 (enExample) 2015-05-21
JP5975581B2 JP5975581B2 (ja) 2016-08-23

Family

ID=46969857

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014504053A Expired - Fee Related JP5975581B2 (ja) 2011-04-07 2012-04-06 ミグラスタチンおよびその使用
JP2016113255A Withdrawn JP2016155873A (ja) 2011-04-07 2016-06-07 ミグラスタチンおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016113255A Withdrawn JP2016155873A (ja) 2011-04-07 2016-06-07 ミグラスタチンおよびその使用

Country Status (7)

Country Link
US (2) US9303009B2 (enExample)
EP (1) EP2693879B1 (enExample)
JP (2) JP5975581B2 (enExample)
CN (1) CN103635088B (enExample)
AU (1) AU2012239977B9 (enExample)
CA (1) CA2832439C (enExample)
WO (1) WO2012139074A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103635088B (zh) 2011-04-07 2016-06-15 索隆-基特林癌症研究协会 米格拉他汀类(Migrastatins)和其用途
US10285646B1 (en) * 2018-02-27 2019-05-14 CeriBell, Inc. Connection quality assessment for EEG electrode arrays
CA3110877A1 (en) 2018-08-27 2020-03-05 Spinogenix, Inc. Fascin binding compounds for spinogenesis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037783A1 (en) 2003-03-28 2007-02-15 Xin-Yun Huang Migrastatin analogs and uses thereof
EP1608626A1 (en) 2003-03-28 2005-12-28 Cornell Research Foundation, Inc. Migrastatin analog compositions and uses thereof
WO2005019181A1 (en) 2003-08-19 2005-03-03 Cornell Research Foundation, Inc. Migrastatin analog cell migration inhibitors
JP5149001B2 (ja) * 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
US8188141B2 (en) * 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
CA2707009A1 (en) 2007-11-21 2009-06-04 Cornell University Methods for inhibiting fascin
CN103635088B (zh) 2011-04-07 2016-06-15 索隆-基特林癌症研究协会 米格拉他汀类(Migrastatins)和其用途

Similar Documents

Publication Publication Date Title
US20220184222A1 (en) Bicycle toxin conjugates and uses thereof
AU2018360766B2 (en) Anticancer agents
JP2019500327A5 (enExample)
CY1121910T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει παραγωγο διυδροκιναζολινης με αντιϊικη δραση
JP2016512563A5 (enExample)
EP4045498B1 (en) Broad spectrum anti-cancer compounds
RU2009138325A (ru) Способ получения кристаллов
JP2013500304A5 (enExample)
ME02400B (me) Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
JP2011523412A5 (enExample)
CY1119880T1 (el) Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων
WO2015183794A1 (en) Tgr5 agonist complexes for treating diabetes and cancer
JP2016506916A5 (enExample)
JP2014511892A5 (enExample)
JP2019501133A5 (enExample)
JP2012525393A5 (enExample)
RU2015118581A (ru) Лиофилизированные препараты мелфалана флуфенамида
JP2015506348A5 (enExample)
PE20130396A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma
JP2013542261A5 (enExample)
UA118010C2 (uk) Інгібітори реплікації вірусів грипу
JP2013509389A5 (enExample)
JP2018510132A5 (enExample)
JP2016517888A5 (enExample)
PE20090876A1 (es) Nuevos derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de cmet